334 related articles for article (PubMed ID: 30820636)
1. Soluble Urokinase-Type Plasminogen Activator Receptor and Arterial Stiffness in Patients with COPD.
Böcskei RM; Benczúr B; Losonczy G; Illyés M; Cziráki A; Müller V; Bohács A; Bikov A
Lung; 2019 Apr; 197(2):189-197. PubMed ID: 30820636
[TBL] [Abstract][Full Text] [Related]
2. Elevated circulating PAI-1 levels are related to lung function decline, systemic inflammation, and small airway obstruction in chronic obstructive pulmonary disease.
Wang H; Yang T; Li D; Wu Y; Zhang X; Pang C; Zhang J; Ying B; Wang T; Wen F
Int J Chron Obstruct Pulmon Dis; 2016; 11():2369-2376. PubMed ID: 27713627
[TBL] [Abstract][Full Text] [Related]
3. The clinical value of suPAR in diagnosis and prediction for patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis.
Huang Q; Xiong H; Shuai T; Wang Y; Zhang C; Zhang M; Zhu L; Lu J; Liu J
Ther Adv Respir Dis; 2020; 14():1753466620938546. PubMed ID: 32643535
[TBL] [Abstract][Full Text] [Related]
4. Soluble urokinase-type plasminogen activator receptor is a novel biomarker predicting acute exacerbation in COPD.
Gumus A; Altintas N; Cinarka H; Kirbas A; Hazıroglu M; Karatas M; Sahin U
Int J Chron Obstruct Pulmon Dis; 2015; 10():357-65. PubMed ID: 25709430
[TBL] [Abstract][Full Text] [Related]
5. The role of serum soluble urokinase-type plasminogen activator receptor in stable chronic obstructive pulmonary disease.
Can Ü; Güzelant A; Yerlikaya FH; Yosunkaya Ş
J Investig Med; 2014 Oct; 62(7):938-43. PubMed ID: 25127435
[TBL] [Abstract][Full Text] [Related]
6. Soluble urokinase-type plasminogen activator receptor as a measure of treatment response in acute exacerbation of COPD.
AboEl-Magd GH; Mabrouk MM
J Bras Pneumol; 2018; 44(1):36-41. PubMed ID: 29538541
[TBL] [Abstract][Full Text] [Related]
7. Soluble urokinase plasminogen activator receptor predicts mortality in exacerbated COPD.
Godtfredsen NS; Jørgensen DV; Marsaa K; Ulrik CS; Andersen O; Eugen-Olsen J; Rasmussen LJH
Respir Res; 2018 May; 19(1):97. PubMed ID: 29783959
[TBL] [Abstract][Full Text] [Related]
8. Exploring soluble urokinase plasminogen activator receptor and its relationship with arterial stiffness in a bi-ethnic population: the SAfrEIC-study.
Schutte AE; Myburgh A; Olsen MH; Eugen-Olsen J; Schutte R
Thromb Res; 2012 Aug; 130(2):273-7. PubMed ID: 22113150
[TBL] [Abstract][Full Text] [Related]
9. Plasma levels of soluble urokinase plasminogen activator receptor (suPAR) and high-sensitivity C-reactive protein after Roux-en-Y gastric bypass or sleeve gastrectomy: a 1-year prospective observational study.
Kokkinos A; Liaskos C; Alexiadou K; Papassotiriou I; Margeli A; Argyrakopoulou G; Perrea D; Alexandrou A; Katsilambros N; Diamantis T; Tentolouris N
J Endocrinol Invest; 2021 Mar; 44(3):599-608. PubMed ID: 32681464
[TBL] [Abstract][Full Text] [Related]
10. Soluble urokinase plasminogen activator receptor (suPAR) levels in healthy pregnancy and preeclampsia.
Toldi G; Bíró E; Szalay B; Stenczer B; Molvarec A; Rigó J; Vásárhelyi B; Bekõ G
Clin Chem Lab Med; 2011 Nov; 49(11):1873-6. PubMed ID: 21722073
[TBL] [Abstract][Full Text] [Related]
11. Soluble urokinase plasminogen activator receptor is associated with subclinical organ damage and cardiovascular events.
Sehestedt T; Lyngbæk S; Eugen-Olsen J; Jeppesen J; Andersen O; Hansen TW; Linneberg A; Jørgensen T; Haugaard SB; Olsen MH
Atherosclerosis; 2011 May; 216(1):237-43. PubMed ID: 21354571
[TBL] [Abstract][Full Text] [Related]
12. Soluble urokinase plasminogen activator receptor levels are elevated and associated with complications in patients with type 1 diabetes.
Theilade S; Lyngbaek S; Hansen TW; Eugen-Olsen J; Fenger M; Rossing P; Jeppesen JL
J Intern Med; 2015 Mar; 277(3):362-371. PubMed ID: 24830873
[TBL] [Abstract][Full Text] [Related]
13. Circulating soluble urokinase plasminogen activator receptor levels and peripheral arterial disease outcomes.
Samman Tahhan A; Hayek SS; Sandesara P; Hajjari J; Hammadah M; O'Neal WT; Kelli HM; Alkhoder A; Ghasemzadeh N; Ko YA; Aida H; Gafeer MM; Abdelhadi N; Mohammed KH; Patel K; Arya S; Reiser J; Vaccarino V; Sperling L; Quyyumi A
Atherosclerosis; 2017 Sep; 264():108-114. PubMed ID: 28728756
[TBL] [Abstract][Full Text] [Related]
14. Soluble urokinase plasminogen activator receptor levels reflect organ damage in systemic lupus erythematosus.
Enocsson H; Wetterö J; Skogh T; Sjöwall C
Transl Res; 2013 Nov; 162(5):287-96. PubMed ID: 23916811
[TBL] [Abstract][Full Text] [Related]
15. Plasma soluble urokinase-type plasminogen activator receptor level is independently associated with coronary microvascular function in patients with non-obstructive coronary artery disease.
Mekonnen G; Corban MT; Hung OY; Eshtehardi P; Eapen DJ; Al-Kassem H; Rasoul-Arzrumly E; Gogas BD; McDaniel MC; Pielak T; Thorball CW; Sperling L; Quyyumi AA; Samady H
Atherosclerosis; 2015 Mar; 239(1):55-60. PubMed ID: 25574858
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic accuracy of soluble urokinase plasminogen activator receptor (suPAR) for prediction of bacteremia in patients with systemic inflammatory response syndrome.
Hoenigl M; Raggam RB; Wagner J; Valentin T; Leitner E; Seeber K; Zollner-Schwetz I; Krammer W; Prüller F; Grisold AJ; Krause R
Clin Biochem; 2013 Feb; 46(3):225-9. PubMed ID: 23159293
[TBL] [Abstract][Full Text] [Related]
17. Circulating soluble urokinase plasminogen activator is elevated in patients with chronic liver disease, discriminates stage and aetiology of cirrhosis and predicts prognosis.
Zimmermann HW; Koch A; Seidler S; Trautwein C; Tacke F
Liver Int; 2012 Mar; 32(3):500-9. PubMed ID: 22098627
[TBL] [Abstract][Full Text] [Related]
18. Plasma-soluble urokinase plasminogen activator receptor (suPAR) levels in Behçet's disease and correlation with disease activity.
Saylam Kurtipek G; Kesli R; Tuncez Akyurek F; Akyurek F; Ataseven A; Terzi Y
Int J Rheum Dis; 2018 Apr; 21(4):866-870. PubMed ID: 27171829
[TBL] [Abstract][Full Text] [Related]
19. Soluble urokinase plasminogen activator receptor predicts mortality in patients with systemic inflammatory response syndrome.
Raggam RB; Wagner J; Prüller F; Grisold A; Leitner E; Zollner-Schwetz I; Valentin T; Krause R; Hoenigl M
J Intern Med; 2014 Dec; 276(6):651-8. PubMed ID: 24645798
[TBL] [Abstract][Full Text] [Related]
20. Soluble urokinase plasminogen activator receptor as a prognostic marker of all-cause and cardiovascular mortality in a black population.
Botha S; Fourie CMT; Schutte R; Eugen-Olsen J; Pretorius R; Schutte AE
Int J Cardiol; 2015 Apr; 184():631-636. PubMed ID: 25771228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
